Welcome to our dedicated page for nasdaq news (Ticker: nasdaq), a resource for investors and traders seeking the latest updates and insights on nasdaq stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect nasdaq's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of nasdaq's position in the market.
Akorn Operating Company LLC has filed for Chapter 7 bankruptcy as of February 23, 2023, ceasing all operations and terminating its US staff. As a result, the company is initiating a voluntary recall of various human and animal drug products that are within their expiry dates. The recall is due to the discontinuation of quality activities, which prevents assurance that products meet intended specifications and may render them adulterated. There are no reports of adverse events related to the recall. Akorn is notifying distributors, requesting that affected products be discarded, and advising consumers to contact their healthcare providers if they have concerns about products in their possession. For further inquiries, consumers can reach Akorn at the specified hotline during business hours.
Akorn Operating Company has launched the first-to-market generic Cetrorelix Acetate for Injection at the ASRM Conference in Anaheim, California. This product serves as a lower-cost alternative for patients undergoing Assisted Reproductive Technology (ART). The FDA granted Akorn a Competitive Generic Therapy designation for Cetrorelix, entitling it to 180 days of market exclusivity. U.S. sales of Cetrorelix are projected at approximately $127 million for 2022, with the drug aimed at preventing premature ovulation during fertility treatments.
Byrna Technologies Inc. (NASDAQ: BYRN) has sold its 40mm legacy business's IP and tooling to Facta Global, retaining exclusive rights to sell the product in the U.S. and South Africa. The deal includes cash and future royalties. Following production issues at its contract manufacturer, Byrna aims to resume supplying the 40mm BIP to U.S. law enforcement as early as July. The partnership with Facta Global, which has extensive experience in law enforcement training and is Byrna's long-time distributor, positions both companies for growth in the less-lethal product market.
Byrna Technologies (NASDAQ: BYRN) reported Q2FY22 revenues of $11.6 million, down 13.3% from $13.4 million in Q2FY21. The company experienced a net loss of $(3.0) million compared to a net income of $2.0 million in the same quarter last year. Gross margin decreased to 52.7% from 56.4%, attributed to higher freight costs and a rise in lower-margin international sales. Byrna reiterated its full-year revenue guidance of $55 - $60 million, aiming for growth through new product launches and market expansion, including the recent acquisition of Fox Labs International.
Byrna Technologies Inc. (NASDAQ: BYRN) has announced a collaboration with Christine Chiu, star of the Netflix series 'Bling Empire,' to promote its non-lethal self-defense products. Through her extensive social media platforms, Chiu aims to raise awareness of Byrna's personal security devices, including the Byrna SD, designed to incapacitate attackers safely. Byrna's Chief Marketing Officer expressed enthusiasm about the partnership, emphasizing the importance of self-defense in today's climate. The Byrna 'Un-Gun' is a portable device shooting irritant projectiles, allowing for effective protection without permanent harm.
Byrna Technologies Inc. (NASDAQ: BYRN) announced a collaboration with Christine Chiu, star of Netflix's 'Bling Empire,' to promote its non-lethal self-defense products. Chiu will utilize her social media platforms to raise awareness about Byrna's personal security devices, including the Byrna SD. The partnership highlights Byrna's 'Live Safe' philosophy, emphasizing the importance of self-defense preparedness. The Byrna SD, which incapacitate attackers without causing permanent harm, is gaining popularity among various supporters, including celebrities and everyday civilians.
Byrna Technologies Inc. (NASDAQ: BYRN) will release its fiscal second quarter financial results for the period ending May 31, 2022, on July 7, 2022, prior to market opening. A conference call is scheduled for the same day at 9:00 am ET to discuss these results. Interested parties can listen via phone or register for a webcast. Following the call, the webcast will be available for 30 days on Byrna's website.
Byrna specializes in non-lethal personal security solutions, including the Byrna® HD device designed for various markets.
On June 17, 2022, Byrna Technologies reported a successful deployment of its Byrna SD less-lethal launchers by the Galveston Police during a high-risk vehicle stop. The incident involved a hit-and-run driver who caused serious injury to a bicyclist. After a brief chase, officers utilized the Byrna SD, resulting in the driver's surrender without further violence. This case highlights the effectiveness of Byrna's products in law enforcement scenarios, emphasizing their non-lethal capabilities to address potentially dangerous situations.
